Testing higher radiation doses guided by PET scans in lung cancer
Tests higher radiation doses in adults with locally advanced non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®
Key facts
- Where
- Aalborg, Aarhus, Copenhagen, Herlev, Næstved, Odense, and Vejle, DenmarkSee the 7 sites
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkNot yet recruiting
- Aarhus University HospitalAarhus, DenmarkTaking people
- RigshospitaletCopenhagen, DenmarkNot yet recruiting
- Herlev University HospitalHerlev, DenmarkTaking people
- Department of Oncology, Naestved HospitalNæstved, DenmarkNot yet recruiting
- Department of Oncology, Odense University HospitalOdense, DenmarkTaking people
- Department of Oncology, Vejle HospitalVejle, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Olfred Hansen
- Trial code
- NCT02354274
- Record updated
- 25 April 2022
- Original description
To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a standard homogeneous dose spreadRead full original descriptionShow less
Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®
To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a standard homogeneous dose spread
Inclusion: Patients with histologically or cytologically proven locally advanced NSCLC stage IIB to IIIB; Performance status 0-1; Able to comply with treatment and follow study and follow-up procedures; Women must have negative pregnancy test; Signed, informed consent; Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two normal tissue must be available.
Exclusion: Former thoracic radiotherapy, unless there is no significant overlap with previous fields; Unable to take oral medications or needing intravenous nutrition; Any unstable systemic disorder (including infection , unstable angina, congestive heart failure , severe liver , kidney or metabolic disease); Any other active malignant disease; Ulcer; Need for nasal oxygen; Nursing women.